Kerbside

Arvind Manor / 08 Jan 2026 / Categories: DSIJ_Magazine_Web, DSIJMagazine_App, Informed Intelligence, Kerbside, Regular Columns

Kerbside

The recommendations provided in this column are taken from various market sources such as brokers, analysts, dealers and investment strategists, etc. These recommendations may not be backed by strong fundamentals. Therefore we advise readers to use their own discretion before investing in these recommendation.

A TIMELY DOSE  [EasyDNNnews:PaidContentStart]

Glenmark Pharmaceuticals Ltd
BSE Code: 532296
CMP: ₹2074.50 

 

The Nifty Pharma index has delivered a multi-month breakout, putting the sector back in the driver’s seat. Glenmark Pharmaceuticals, a key index constituent, is now on the verge of its own breakout—making it a timely name to track as pharma momentum builds. Glenmark is a research-led global pharma company with presence across Branded, Generics and OTC, focused on respiratory, dermatology and oncology. The company recently launched Epinephrine Injection USP, 30 mg/30 mL (1 mg/mL) Multiple-Dose Vial, strengthening its injectable portfolio in the U.S. institutional market with a bioequivalent and therapeutically equivalent product. The launch targets a U.S. market with annual sales of about $67.6 million, offering a defined revenue opportunity and supporting Glenmark’s North America injectable expansion. A stock to keep on radar

SOMETHING IS COOKING 

Redington
BSE Code: 532805
CMP: ₹285.60 

Redington ranks among the world’s top ten technology distributors—an achievement that stands out even more because it operates without a presence in the three largest IT markets: the United States, Europe and China. Now, the street chatter is adding spice. There are murmurs of a positive development that could be announced soon, and the stock has already started showing signs of attention with a noticeable spike in volumes in recent sessions. In markets, volume often speaks before headlines do. If the buzz turns into a confirmed trigger, this could shift from “watchlist” to “actionable” faster than most investors expect. 

DESIGNING THE NEXT WAVE 

Tata Elxsi
BSE Code: 500408
CMP: ₹5,343.15 

Tata Elxsi is among the world’s leading providers of design and technology services, with a strong presence across Transportation, Media, Communications and Healthcare & Medical Devices. Transportation is the key growth engine, contributing over 53 per cent of total revenue, and the pipeline is showing solid momentum— driven by global OEM SDV programmes and large deal wins. The adjacency strategy is also delivering, supported by fresh customer additions and new wins. In Aerospace & Defence, the company has secured a turnkey airport guidance systems development programme from a U.S.-headquartered aerospace supplier, signalling expanding capability beyond its core. Management expects better traction in H2 versus H1, with Europe improving and Japan remaining a bright spot. Keep it on your radar 

TECHNICALLY SOUND 

Natco Pharma
BSE Code: 524816
CMP: ₹926.20 

 

Natco Pharma manufactures and distributes generic and branded formulations, specialty pharmaceuticals, active pharmaceutical ingredi ents (APIs) and crop protection products—giving it a diversified footprint within the broader health care and agri-chem space. What’s putting the stock back in focus is the tape. A technical analyst from a leading brokerage house has flagged Natco Pharma with a buy call, citing that the technical picture has turned favourable. The view is for a double-digit upside over the medium term based on the improved chart setup. If you track price-action-led ideas, this is one to keep on your radar 

(Closing price as of January 06, 2026)

[EasyDNNnews:PaidContentEnd] [EasyDNNnews:UnPaidContentStart]

[EasyDNNnews:UnPaidContentEnd]